CARY, N.C., Sept. 24, 2025 – Biologics by McKesson is proud to announce the launch of Amtagvi® (lifileucel), the newest addition to our expanding commercial cell and gene therapy portfolio. Biologics, in partnership with InspiroGene™, is the specialty pharmacy for this newly FDA-approved treatment.
Amtagvi is the first FDA-approved, one-time tumor-infiltrating lymphocyte (TIL) therapy for a solid tumor. It’s used to treat patients with unresectable or metastatic melanoma, offering a new path forward by using a patient’s own immune cells to fight their cancer.
Read the full McKesson press release: HERE